Agregador

Funding Opportunity PAR-25-437 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement with Special Receipt, Referral, and/or Review Considerations (PAR) is to solicit applications to access limited identifiable data or biospecimens from the ECHO Cohort to study high-priority areas of maternal and child health.

DOE : Indiana University: Department Chair of Intelligent Systems Engineering Appointment Status: Tenure Department: IU Bloomington Intelligent Systems Engineering Location:... Bloomington, Indiana

Notice NOT-OD-25-127 from the NIH Guide for Grants and Contracts

Competitive salary, adequate to seniority: FONDAZIONE TELETHON ETS: Fondazione Telethon is seeking Group Leaders and Postdoctoral Researchers to advance translational research on rare diseases. Italy

CONCLUSIONS: Advanced GC/GEJC patients treated with tislelizumab plus chemotherapy versus placebo plus chemotherapy in first-line had sustained and improved HRQoL. These results, along with previous efficacy and safety data, support tislelizumab plus chemotherapy as a first-line treatment option for GC/GEJC.Trial registration: The RATIONALE-305 trial is registered on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT03777657).

Testicular cancer primarily manifests as a painless mass, yet atypical presentations can hinder effective diagnosis and management. Here we present a 34-year-old male with a large, ulcerated, fungating extra-scrotal mass invading the inguinal canal. Laboratory showed markedly elevated alpha-fetoprotein, and imaging confirmed advanced disease with bilateral pulmonary metastases. The patient underwent radical orchiectomy with partial scrotectomy. Histopathology revealed a pure post-pubertal yolk...

Salary will be commensurate with qualifications and experience.: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine: Postdoctoral Fellows to explore 1). LNP-mediated gene therapy, 2). PROTACs targeting intracellular kinases, 3). Proteomics-based biomarker discovery. Shanghai (CN) Huangpu District

Notice NOT-MH-25-215 from the NIH Guide for Grants and Contracts

Attractive salary packages are offered, negotiable based on individual qualifications and needs.: Hangzhou Dianzi University: Various positions are open, including:Lixing Chair-professor, Lixing Distinguished-professor, etc. Hangzhou, Zhejiang (CN)

$62,000 - $72,000 000 (depending on experience) + benefits: SUNY Downstate Health Sciences University: Post-Doctoral Positions To Study Mechanisms Of Translation And Translation-Associated Quality Control Processes Brooklyn, New York (US)

Baylor College of Medicine: The Department of Medicine at Baylor College of Medicine is seeking an experienced, reliable and enthusiastic Senior Research Administration Associ... Houston, TX

Competitive: University of Texas MD Anderson Cancer Center: Postdoctoral positions are available immediately to work in the areas of DNA damage repair and cancer biology. The lab focuses on the roles of tumo... Houston, Texas

Competitive salary: Shenzhen Bay Laboratory: Shenzhen Bay Laboratory (SZBL) sincerely invites outstanding talents of all levels in biomedical frontier research from well-known universities and... Shenzhen, Guangdong (CN)

Commensurate with education and experience: University of Kansas - Department of Pharmacology & Toxicology: The University of Kansas invites applications for a faculty position at the assistant professor level in Pharmacology and Toxicology. Lawrence, Kansas (US)

Subject upon Applicant : Iowa State University- Department of Chemistry: The Department of Chemistry at Iowa State University seeks outstanding candidates for the prestigious Barton Chair position, a tenured appointment. Ames, Iowa

Notice NOT-OD-25-125 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-383 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this NOFO or any of the companion opportunities. For more information see BP MedTech website.

Funding Opportunity PAR-25-442 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for exploratory and early-stage projects that focus on undruggable target classes within intractable human disease. Applicants will identify a human disease relevant undruggable target class and develop a method or agent that is selective for one or more targets within that target class. This NOFO is intended to jumpstart research that demonstrates innovative strategies to modulate targets that cannot be addressed by established therapeutic types, furthering the development of methods and/or agents selective for undruggable target classes.

Penetrating cardiac injuries (PCI) from gunshot wounds are among the most fatal forms of trauma, with prehospital mortality rates exceeding 90%. While the right ventricle is most commonly affected due to its anterior location, retained intracardiac projectiles are rarely encountered and pose significant management challenges. Cardiac tamponade, though potentially fatal, can sometimes provide a protective mechanism by limiting hemorrhage. The decision to surgically remove retained bullets remains...

Penetrating cardiac injuries (PCI) from gunshot wounds are among the most fatal forms of trauma, with prehospital mortality rates exceeding 90%. While the right ventricle is most commonly affected due to its anterior location, retained intracardiac projectiles are rarely encountered and pose significant management challenges. Cardiac tamponade, though potentially fatal, can sometimes provide a protective mechanism by limiting hemorrhage. The decision to surgically remove retained bullets remains...